Berger A, Ramirez A J
Catedra de Farmacologia Facultad de Farmacia y Bioquimica, University of Buenos Aires, Argentina.
J Hypertens Suppl. 1988 Dec;6(4):S514-7. doi: 10.1097/00004872-198812040-00162.
Both endogenous opiate peptides and serotonin are known to be involved in blood pressure control. In this work we present results obtained in anaesthetized normotensive rats in which we studied the possible interaction between the central blood pressure effects induced by methionin (met)-enkephalin and serotonergic pathways. Met-enkephalin administered intracerebroventricularly produced a dose-dependent hypotensive action that was prevented by pretreating the animals with naloxone (opioid antagonist), or with methiothepin (serotonergic S1 and S2 receptor antagonist) or 5,7-dihydroxytryptamine (a serotonergic neurotoxin). In contrast, ritanserin, a serotonergic S2 receptor antagonist, failed to alter the hypotensive action of met-enkephalin. These data suggest that the central activation of opiate receptors induces a hypotensive action in which a serotonergic pathway is required. In this case the serotonergic receptor involved seems to belong to the S1 subtype.
已知内源性阿片肽和5-羟色胺均参与血压调控。在本研究中,我们呈现了在麻醉的正常血压大鼠中所获得的结果,在此研究中,我们探究了甲硫氨酸(met)-脑啡肽诱导的中枢性血压效应与5-羟色胺能通路之间可能存在的相互作用。脑室内注射met-脑啡肽会产生剂量依赖性的降压作用,用纳洛酮(阿片类拮抗剂)、甲硫噻庚因(5-羟色胺能S1和S2受体拮抗剂)或5,7-二羟基色胺(一种5-羟色胺能神经毒素)预处理动物可预防该作用。相反,5-羟色胺能S2受体拮抗剂利坦色林未能改变met-脑啡肽的降压作用。这些数据表明,阿片受体的中枢激活会诱导一种降压作用,其中需要一条5-羟色胺能通路。在这种情况下,所涉及的5-羟色胺能受体似乎属于S1亚型。